MAGE-A4-TCRS

European patent · EP3946621 · In force

Register entry

Publication number
EP3946621
Application number
EP20719942
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Mar 27, 2020
Published
Feb 9, 2022
Granted
May 21, 2025
Protection ends at the latest
Mar 26, 2040
Next annual fee due
Mar 31, 2027
IPC classes
A61P 35/00 (2006.01)
C07K 14/47 (2006.01)
C07K 14/725 (2006.01)
A61K 38/00 (2006.01)
Priority
EP 19165387 27.03.2019
PCT application
PCT/EP2020/058779 27.03.2020
PCT publication
WO2020/193767 01.10.2020
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 2, 2026

    Change

    Published in Swissreg on 02.04.2026

  2. Apr 1, 2026

    Change

    Published in Swissreg on 01.04.2026

  3. Aug 13, 2025

    Agent entered

    Representative
    VALIPAT, c/o BOVARD LTD, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 13.08.2025

  4. May 21, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 21.05.2025

Parties

Holder

Medigene Immunotherapies GmbH

Lochhamer Straße 11, 82152 Planegg-Martinsried, DE

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road, Tarrytown, NY 10591, US

Agent

VALIPAT c/o BOVARD LTD

Optingenstrasse 16, 3013 Bern

Inventor

ELLINGER, Christian

80337 Munich, DE

SOMMERMEYER, Daniel

80638 Munich, DE

BLACKBURN PARSONS, Geoffrey

Jamaica Plain, Massachusetts 02130, US

MANN, Jasdeep

Lake Forest Park, Washington 98155, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.